Sophie Neumann-Piperno

Sophie Neumann-Piperno

Paris, 75005, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 193 publications

Safety and outcome of transscleral fine-needle aspiration biopsy in uveal melanoma: 10-year experience in 347 cases.

Safety and outcome of transscleral fine-needle aspiration biopsy in uveal melanoma: 10-year experience in 347 cases.

Journal: Retina (Philadelphia, Pa.)

Published: June 15, 2026

Five-year survival with tebentafusp in metastatic uveal melanoma.

Five-year survival with tebentafusp in metastatic uveal melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 02, 2026

Total tumor volume and growth rate at 3 months on MRI outperform baseline imaging and circulating tumor DNA for predicting survival of patients with metastatic uveal melanoma receiving tebentafusp.

Total tumor volume and growth rate at 3 months on MRI outperform baseline imaging and circulating tumor DNA for predicting survival of patients with metastatic uveal melanoma receiving tebentafusp.

Journal: Diagnostic and interventional imaging

Published: December 09, 2025

An anti-PMEL antibody-drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial.

An anti-PMEL antibody-drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial.

Journal: Nature medicine

Published: November 17, 2025

ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 10, 2025

ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 10, 2025

Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.

Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.

Journal: ESMO open

Published: September 24, 2025

Uveal Melanoma: Changing Paradigms of Treatment.

Uveal Melanoma: Changing Paradigms of Treatment.

Journal: Ocular oncology and pathology

Published: September 04, 2025

Uveal Melanoma and the Lynch Syndrome Tumor Spectrum.

Uveal Melanoma and the Lynch Syndrome Tumor Spectrum.

Journal: JAMA ophthalmology

Published: June 18, 2025

Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.

Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 12, 2025

Outcome of 1773 superficial non-dermatofibrosarcoma sarcomas A French Sarcoma Group study (FSG) from the NETSARC database.

Outcome of 1773 superficial non-dermatofibrosarcoma sarcomas A French Sarcoma Group study (FSG) from the NETSARC database.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 21, 2025

Real-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN Expert Centres.

Real-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN Expert Centres.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 09, 2025

Showing 1-12 of 193

Last Updated: 09/26/2026